HKSE:06922 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:06922 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Cryofocus Medtech (Shanghai) Co's enterprise value is HK$1,206.23 Mil. Cryofocus Medtech (Shanghai) Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$45.07 Mil. Therefore, Cryofocus Medtech (Shanghai) Co's EV-to-Revenue for today is 26.76.
The historical rank and industry rank for Cryofocus Medtech (Shanghai) Co's EV-to-Revenue or its related term are showing as below:
During the past 4 years, the highest EV-to-Revenue of Cryofocus Medtech (Shanghai) Co was 148.31. The lowest was 24.46. And the median was 68.40.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2025-03-04), Cryofocus Medtech (Shanghai) Co's stock price is HK$4.80. Cryofocus Medtech (Shanghai) Co's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.19. Therefore, Cryofocus Medtech (Shanghai) Co's PS Ratio for today is 25.40.
The historical data trend for Cryofocus Medtech (Shanghai) Co's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
EV-to-Revenue | - | - | 132.10 | 98.50 |
Cryofocus Medtech (Shanghai) Co Semi-Annual Data | ||||||||
Dec20 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | Jun24 | ||
EV-to-Revenue | Get a 7-Day Free Trial | - | 132.10 | - | 98.50 | - |
For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Cryofocus Medtech (Shanghai) Co's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 1206.231 | / | 45.069 | |
= | 26.76 |
Cryofocus Medtech (Shanghai) Co's current Enterprise Value is HK$1,206.23 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryofocus Medtech (Shanghai) Co's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$45.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryofocus Medtech (Shanghai) Co (HKSE:06922) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Cryofocus Medtech (Shanghai) Co's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 4.80 | / | 0.189 | |
= | 25.40 |
Cryofocus Medtech (Shanghai) Co's share price for today is HK$4.80.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Jun. 2024 was HK$0.19.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhuhai Junheng Investment L.p. (limited Partnership) | 2101 Beneficial owner | |
Shang Hai Shi Di Sheng Wu Ke Ji You Xian Gong Si | ||
Lv Shiwen | 2103 Interests held jointly with another person | |
Shenzhen Gao Ling Tiancheng Iii Investment Co., Ltd. | 2201 Interest of corporation controlled by you | |
Ning Bo Lin Feng Sheng Wu Ke Ji You Xian Gong Si | ||
Wu Jianhui | 2101 Beneficial owner | |
Li Hui | 2202 Interest of your spouse | |
Shang Hai Shi Di Shi Ye Fa Zhan You Xian Gong Si | ||
Sun Xiaolu | 2201 Interest of corporation controlled by you | |
Fu Guo Ji Jin Guan Li You Xian Gong Si | 2102 Investment manager | |
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi He Huo Qi Ye You Xian He Huo | ||
Shang Hai Bi Lin Xing Zi Chan Guan Li You Xian Gong Si | ||
Hang Zhou Bi Lin Xing Chuang Xin Tou Zi Guan Li He Huo Qi Ye You Xian He Huo | ||
Sheng Shan Zi Chan Guan Li Shang Hai You Xian Gong Si | ||
Gan Shi Xiong |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.